Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Gatekeeper mutations in BRAF confer drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“Notably, an isoleucine for threonine substitution of the gatekeeper in BCR-ABL mediates imatinib resistance in chronic myelogenous leukemia (28).”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“However, the lack of clinical activity of sorafenib in melanoma (30) suggests that sorafenib is unable to inhibit BRAF in vivo through this mechanism either.”
BackgroundMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Cited by
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
“We did not detect mutation in BRAF at the gatekeeper sit”
BackgroundTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Self-citationTumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“Whittaker et al. (2010) provided evidence against the dogma that sorafenib’s effects were primarily against BRAF.”
Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7680 · Cited by 386
Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., & Gilmer, T. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0989 · Cited by 363
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 359
Self-citationMaking sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Sievert, A. J., Lang, S.-S., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P. B., & Resnick, A. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219232110 · Cited by 285
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 250
“Somewhat unexpectedly, secondary mutations that disrupt inhibitor binding have not been observed, even though mutation of the B-Raf gatekeeper site is known to prevent drug binding (Whittaker et al. 2010).”
BackgroundGirotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
“Ba/F3 cells grow in an interleukin-3 (IL-3)-dependent manner, but when transformed with BRAF V600E and BRAF T529N,V600E , their growth becomes IL-3 independent but dependent on oncogenic BRAF (Whittaker et al., 2010a).”
InfluentialSelf-citationXie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002037 · Cited by 165
“In another example, moderate micomolar RAF inhibitor PLX4720 is potent in inhibiting downstream signaling and proliferation of the cell harboring BRAF, and in treating melanoma cell lines [56].”
BackgroundResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
“While the gatekeeper threonine mutation has been identified as an in vitro cause of BRAF inhibitor resistance, this mutation has not been seen in patients.(18) This may be because many BRAF inhibitors induce paradoxical activation of wild-type RAF.”
BackgroundBRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Vin, H., Ojeda, S. S., Ching, G., Leung, M. L., Chitsazzadeh, V., Dwyer, D. W., Adelmann, C. H., Restrepo, M., Richards, K. N., Stewart, L. R., et al. (2013) · eLife · doi:10.7554/elife.00969 · Cited by 84
“Gatekeeper mutant kinases, in which the threonine (T) is replaced by a larger amino acid, in our case glutamine (Q), are often rendered insensitive to small molecule inhibitors and are an important mechanism of drug resistance ( Daub et al., 2004 ; Whittaker et al., 2010 ).”
Metadata
- Authors
- Whittaker, S., Kirk, R., Hayward, R., Zambon, A., Viros, A., Cantarino, N., Affolter, A., Nourry, A., Niculescu-Duvaz, D., Springer, C., & Marais, R.
- Venue
- Science Translational Medicine
- Published
- 2010-06-09
- Volume
- 2
- Issue
- 35
- Pages
- 35ra41-35ra41
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2032210521
- Cited by
- 156
- References
- 6
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.